Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CYP2E1 TB study

ABSTRACT: CYP2E1 gene sequencing data for the drug-susceptible TB study sample set (n = 34)

PROVIDER: PRJEB69677 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR12268300_1.fastq.gz	Fastqsanger.gz
	ERR12268300_2.fastq.gz	Fastqsanger.gz
	ERR12268302_1.fastq.gz	Fastqsanger.gz
	ERR12268302_2.fastq.gz	Fastqsanger.gz
	ERR12268303_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 108

Similar Datasets

Total RNA-seq using mouse tissues from Cyp2e1 +/+ mice upon pair-fed, Cyp2e1 +/+ mice upon EtOH-fed, Cyp2e1 -/- mice upon pair-fed, and Cyp2e1 -/- mice upon EtOH fed.

Project description:To investigate the effect of Cyp2e1 and EtOH on mRNA expression in mouse tissues, we profiled total RNA expression using mouse tissues from Cyp2e1 -/- mice and Cyp2e1 +/+ mice upon EtOH fed mice compared to control. We compare the expression level of RNA and profile circular RNA expression using circular RNA junction.

2024-06-30 | GSE206348 | GEO

Transcriptome profiling of normal and CYP2E1 knockdown human neural progenitor cells

Project description:The objective of the study was to examine changes in gene expression induced by CYP2E1 knockdown in neural progenitor cells.There were 6samples in total.Samples shs_1, shs_2, and shs_3 are the control group, and shCYP2E1_1, shCYP2E1_2, and shCYP2E1_3 are the CYP2E1 knockdown group.Neural progenitor cells were cultured in vitro from normal fetal brain tissue aborted at 21 weeks, infected with CYP2E1_shRNAs and CYP2E1_shRNA lentivirus respectively, and then differentiated and cultured for 4 days.The total RNA of each sample was extracted from the lentivirus infected, early differentiated human neural progenitor cells with TRIzol reagent.Then the RNA samples were processed for high throughput transcriptome sequencing on Illumina HiSeq 3000 platform.

2025-08-31 | GSE278691 | GEO

Q11, a CYP2E1 inhibitor, exerts anti-hepatocellular carcinoma effect by inhibiting M2 macrophage polarization

Project description:Despite significant advancements in cancer immunotherapy, many patients continue to respond poorly. Novel therapeutic strategies and drugs are urgently needed. Here, we found that CYP2E1 is significantly upregulated in M2 macrophages. The CYP2E1 inhibitor, Q11, could inhibit M2 macrophage polarization, while CYP2E1 overexpression could promote it. Increased levels of CYP2E1 and M2 macrophages in the tumor microenvironment of HCC patients correlate with poor prognosis. Q11 could inhibit tumor cells by targeting M2 macrophages rather than directly attacking tumor cells. Both Q11 and Cyp2e1 knockout could effectively suppress tumor growth. Q11 reduces the production of CYP2E1 metabolites (±)9(10)-DiHOME and (±)12(13)-DiHOME, thus attenuating PPARγ activation and M2 macrophage polarization. In summary, our findings suggest that Q11 could suppress M2 macrophage polarization by modulating the CYP2E1/(±)9(10)-DiHOME or (±)12(13)-DiHOME/PPARγ axis, indicating that CYP2E1 inhibition may be a novel therapeutic strategy for HCC and positioning Q11 as a promising therapeutic agent.

2024-12-26 | GSE282907 | GEO

Total RNA-seq using mouse tissues from Cyp2e1 +/+ mice upon pair-fed, Cyp2e1 +/+ mice upon EtOH-fed, Cyp2e1 -/- mice upon pair-fed, and Cyp2e1 -/- mice upon EtOH fed.

Project description:Total RNA-seq using mouse tissues from Cyp2e1 +/+ mice upon pair-fed, Cyp2e1 +/+ mice upon EtOH-fed, Cyp2e1 -/- mice upon pair-fed, and Cyp2e1 -/- mice upon EtOH fed.

| PRJNA850373 | ENA

Epigenetics and Proteomics join Transcriptomics on the quest towards TB Biomarkers

Project description:Even though recent reports estimate a reduction in the spread and contraction of Tuberculosis (TB), 30 % of the world population are currently being latently infected by Mycobacterium tuberculosis (Mtb). This latent infection can at any time develop into active disease. Biomarkers to monitor this process as well as biomarkers for disease susceptibility and TB diagnosis is urgently needed in order to facilitate a more drastic decrease in the spread of Mtb and better care for TB patients. Our understanding of biology combined with evolving technical advances in high-throughput techniques, led us to investigate the possibility of additional role players (epigenetics and proteomics) in the quest to (a) understand the biology of TB host response and (b) search for biomarkers in TB diagnostics and –susceptibility. We engaged in a pilot study, using a relatively small sample set to interrogate the DNA methylome, transcriptome and proteome in monocytes and granulocytes of TB patients and healthy latently infected participants. The observations in this study provide a first glimpse at the level- and sources of diversity in the epigenome and proteome amongst TB patients and latently infected controls despite limitations due to small sample size. Functionally the differences between the disease phenotypes observed in the different platforms were congruent and suggest regulation of function not only at the transcriptional level, but also by DNA methylation and microRNA. We conclude that the current data support the notion to develop a large scale study of especially the DNA methylome while care should be taken in the study design to account for variation based on gender, age and cell type.

2015-08-26 | PXD001960 | Pride

TB Virulence Study

Project description:TB Virulence Study

| PRJEB29199 | ENA

Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity

Project description:We report the discrepancy of hepatic mRNA expression in Cyp2e1 widetype and knockout mice by application of RNA-seq technology.

2022-06-01 | GSE193796 | GEO

Proteomics of human sputum from TB patients with high and low calprotectin

Project description:Sputum supernatant samples were collected from patients with and without active tuberculosis. Calprotectin was quantified and a total of twelve samples were selected for LC-MS/MS. Six samples were from patients with active TB and six samples were from TB-negative patients. Of the six samples from TB and non-TB sets, three samples had low concentrations of calprotectin and three samples had high concentrations of calprotectin. Overall, there were four groups with three samples each: non-TB with low CP, non-TB with high CP, TB with low CP, and TB with high CP. Each sample was prepared in technical triplicate, thus there were a total of 36 samples prepared for LC-MS/MS.

2025-07-23 | PXD065067 | Pride

Blood transcriptional signatures of asymptomatic FDG-PET/CT-defined Subclinical TB lesions and their prediction of future TB progression

Project description:Diagnostic tests for tuberculosis (TB) infection poorly predict future incident disease risk. We investigated a cohort of asymptomatic HIV-uninfected household contacts of TB in South Africa in which baseline lung lesions indicative of Subclinical TB identified by [18F]-fluoro-2-deoxy-D-glucose (FDG)-positron emission/computed tomography (PET/CT) had high predictive value for future TB over 5 years. RNA-sequencing analysis of whole blood samples at baseline PET/CT, 5-15m PET/CT2, and the TB diagnosis of incident TB revealed persistent enrichment of neutrophil and monocyte transcriptional modules in those with Subclinical TB and worsening and discrete lung abnormalities, while expression of a core set of type I IFN genes related to FDG-avid lymph nodes. Leveraging multiple machine learning algorithms, we derived gene signatures of various PET/CT lesion Subclinical phenotypesTB, future lesion worsening and TB diagnosis. prevalent and incident TB. Validating signatures in two independent cohorts against TB progression within 6,12,18 and fup to 24-29-months, confirmed gave AUC of 0.75-0.95 and 0.77-0.87 with performance above optimal sensitivity and wminimum specificity for the WHO target product profile for TB progression.

2025-08-09 | GSE240463 | GEO

Blood transcriptional signatures of asymptomatic FDG-PET/CT-defined Subclinical TB lesions and their prediction of future TB progression II

2025-09-06 | GSE242685 | GEO